TOKYO, Nov 20, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor "TASFYGO Tablets 35mg" ...
More than a thousand people in England with a specific type of advanced breast cancer could benefit from a new once-a-day tablet following a decision by the National Institute for Health and Care ...
A tablet for the most common form of bladder cancer has been given the green light for use by the NHS. The recommendation on erdafitinib by the National Institute of Health and Care Excellence (Nice) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback